CO vs. VMD, QIPT, CORBF, MRAI, BRTX, MGRX, OTRK, NIVF, FMS, and DVA
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Viemed Healthcare (VMD), Quipt Home Medical (QIPT), Global Cord Blood (CORBF), Marpai (MRAI), BioRestorative Therapies (BRTX), Mangoceuticals (MGRX), Ontrak (OTRK), NewGenIvf Group (NIVF), Fresenius Medical Care (FMS), and DaVita (DVA). These companies are all part of the "miscellaneous health & allied services, not elsewhere classified" industry.
Global Cord Blood vs.
Global Cord Blood (NYSE:CO) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings.
Global Cord Blood received 377 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 76.46% of users gave Global Cord Blood an outperform vote while only 42.86% of users gave Viemed Healthcare an outperform vote.
In the previous week, Global Cord Blood and Global Cord Blood both had 2 articles in the media. Viemed Healthcare's average media sentiment score of 1.71 beat Global Cord Blood's score of 0.23 indicating that Viemed Healthcare is being referred to more favorably in the news media.
74.2% of Viemed Healthcare shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by insiders. Comparatively, 20.0% of Viemed Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Global Cord Blood has higher revenue and earnings than Viemed Healthcare. Global Cord Blood is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.
Global Cord Blood has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
Viemed Healthcare has a net margin of 4.87% compared to Global Cord Blood's net margin of 0.00%. Viemed Healthcare's return on equity of 8.72% beat Global Cord Blood's return on equity.
Summary
Viemed Healthcare beats Global Cord Blood on 11 of the 16 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Global Cord Blood Competitors List
Related Companies and Tools
This page (NYSE:CO) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy CO Stock Free CO Stock Alerts